Merck KGaA ADR MKKGY
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MKKGY is a good fit for your portfolio.
News
-
Merck KGaA FY24 Outlook Improves After Strong Second Quarter
-
Germany's Merck to Sell Surface Solutions Unit For $721 Million
-
Germany's Merck to Buy Unity-SC for at Least $170 Million
-
ASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts
-
German Stocks Fall Tuesday
-
Germany's Merck Group shares drop 10% after scrapping trial of promising cancer drug
-
Merck KGaA Shares Drop After Canceled Late-Stage Cancer Drug Study
-
Merck KGaA Signs Korea Science Research Pact
Trading Information
- Previous Close Price
- $33.46
- Day Range
- $34.22–35.50
- 52-Week Range
- $28.59–38.26
- Bid/Ask
- $34.91 / $35.42
- Market Cap
- $76.04 Bil
- Volume/Avg
- 230,396 / 42,650
Key Statistics
- Price/Earnings (Normalized)
- 21.83
- Price/Sales
- 3.36
- Dividend Yield (Trailing)
- 1.35%
- Dividend Yield (Forward)
- 1.35%
- Total Yield
- 1.35%
Company Profile
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 62,345
- Website
- https://www.emdgroup.com
Competitors
Valuation
|
Metric
|
MKKGY
|
BIIB
|
TMO
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.83 | 14.07 | 28.08 |
Price/Book Value | 2.52 | 2.01 | 4.89 |
Price/Sales | 3.36 | 3.18 | 5.53 |
Price/Cash Flow | 16.06 | 13.15 | 27.23 |
Price/Earnings
MKKGY
BIIB
TMO
Financial Strength
|
Metric
|
MKKGY
|
BIIB
|
TMO
|
|---|---|---|---|
Quick Ratio | 0.72 | 0.95 | 1.19 |
Current Ratio | 1.29 | 2.10 | 1.70 |
Interest Coverage | 10.23 | 5.38 | 4.83 |
Quick Ratio
MKKGY
BIIB
TMO
Profitability
|
Metric
|
MKKGY
|
BIIB
|
TMO
|
|---|---|---|---|
Return on Assets (Normalized) | 5.60% | 8.32% | 8.69% |
Return on Equity (Normalized) | 10.13% | 15.02% | 18.71% |
Return on Invested Capital (Normalized) | 7.63% | 10.29% | 10.97% |
Return on Assets
MKKGY
BIIB
TMO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Zlstxrwdgf | Qkbl | $82.1 Bil | |||
| Haleon PLC ADR
HLN
| Gvdcftkx | Bvcd | $41.4 Bil | |||
| Viatris Inc
VTRS
| Yhrwybxlz | Gyf | $14.4 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Kqtptzwn | Gxscd | $13.7 Bil | |||
| Catalent Inc
CTLT
| Pzrqgfny | Dxrrzwx | $10.6 Bil | |||
| Perrigo Co PLC
PRGO
| Nktpmggf | Ghwv | $3.8 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Qnckdbzdb | Llpcxfx | $3.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Vbtzwnfw | Cxxy | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Vthnljpfl | Plrf | $2.7 Bil |